Zoetis Inc. (NYSE:ZTS) Shares Purchased by Shepherd Financial Partners LLC

Shepherd Financial Partners LLC boosted its position in Zoetis Inc. (NYSE:ZTS) by 4.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,938 shares of the company’s stock after buying an additional 383 shares during the period. Shepherd Financial Partners LLC’s holdings in Zoetis were worth $1,456,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of ZTS. Darwin Wealth Management LLC purchased a new position in shares of Zoetis during the third quarter worth $31,000. First Personal Financial Services purchased a new position in shares of Zoetis during the 3rd quarter valued at about $33,000. Capital Performance Advisors LLP purchased a new position in shares of Zoetis during the 3rd quarter valued at about $33,000. Dunhill Financial LLC lifted its holdings in shares of Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after buying an additional 75 shares during the period. Finally, Fortitude Family Office LLC boosted its stake in shares of Zoetis by 1,387.5% in the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after buying an additional 222 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. JPMorgan Chase & Co. upped their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Morgan Stanley cut their price target on Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. UBS Group initiated coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Finally, Leerink Partners started coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $215.00.

Zoetis Stock Performance

Shares of Zoetis stock opened at $171.37 on Friday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The business’s 50 day moving average price is $169.34 and its 200 day moving average price is $179.28. The company has a market cap of $77.32 billion, a price-to-earnings ratio of 32.21, a PEG ratio of 2.77 and a beta of 0.90. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.17%. Zoetis’s payout ratio is 37.59%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.